查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1595127

卵巢癌治疗市场：按药物类别、治疗方式和药物 - 2025-2030 年全球预测

Ovarian Cancer Drugs Market by Therapeutics Class (Angiogenesis Inhibitors, PARP Inhibitors, PD-L1 Inhibitors), Modality (Chemotherapy, Hormonal Therapy, Targeted Therapy), Drugs - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年卵巢癌治疗市场价值为39.5亿美元，预计到2024年将达到44.9亿美元，复合年增长率为13.75%，到2030年将达到97.3亿美元。

卵巢癌治疗市场的范围包括针对卵巢癌的药物治疗的开发、生产和分销。这包括化疗药物、标靶治疗和免疫治疗。卵巢癌的高死亡率凸显了对卵巢癌治疗的需求，其主要原因往往是晚期诊断，因此为了提高存活率和患者预后，有效的药物治疗至关重要。治疗的主要用途主要是肿瘤科医师和医疗机构的治疗系统，最终用途范围包括医院、专门的癌症治疗中心和诊所。

主要市场统计
基准年[2023] 39.5亿美元
预测年份 [2024] 44.9亿美元
预测年份 [2030] 97.3亿美元
复合年增长率（%） 13.75%

市场成长受到个人化医疗进步、研发投资增加以及全球疾病意识增强等因素的显着影响。包括标靶治疗疗法和联合治疗在内的创新治疗方法的兴起提供了巨大的成长潜力，新药监管核准的增加也带来了巨大的成长潜力。对微创治疗方案和改善治疗效果的需求不断增长也为市场扩张创造了新的机会。利用这些机会的建议包括投资精准肿瘤学和透过策略联盟加强患者的可及性。

然而，市场面临高昂的药物开发成本、严格的监管要求以及与现有疗法相关的潜在副作用等限制。此外，卵巢癌的遗传多样性使得开发一种通用的治疗方法变得困难，并且通常需要复杂的治疗策略。

需要技术创新的领域包括开发用于早期检测的生物标记、开发新的药物传输系统以及利用人工智慧和基因组知识的针对患者的特异性治疗方法。此外，这个市场的性质既是竞争性的，也是协作性的，製药公司、生技公司和研究机构形成伙伴关係。专注于突破性治疗方法和适应性临床试验设计的公司将在这个不断发展的市场格局中处于领先地位。鑑于这些动态，相关人员应优先考虑以患者为中心的设计和数位整合医疗保健解决方案，以促进长期创新和成长。

市场动态：揭示快速发展的卵巢癌药物市场的关键市场洞察

供需的动态交互作用正在改变卵巢癌药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球卵巢癌发生率上升
    • 世界女性老化人口成长
    • 新药采用和强大的开发平臺
  • 市场限制因素
    • 抗癌药物对人体的不良影响
  • 市场机会
    • 政府增加对新兴国家医疗保健产业的资助
    • 新兴经济体卵巢癌药物的开发
  • 市场挑战
    • 卵巢癌治疗费用高

波特五力：驾驭卵巢癌药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解卵巢癌药物市场的外部影响

外部宏观环境因素在塑造卵巢癌治疗药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解卵巢癌治疗药物市场的竞争状况

卵巢癌治疗药物市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵卵巢癌治疗市场供应商的绩效评估

FPNV定位矩阵是评估卵巢癌治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划卵巢癌治疗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对卵巢癌治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球卵巢癌发生率增加
      • 世界各地老年妇女的数量正在增加。
      • 新药推出和强大的开发平臺
    • 抑制因素
      • 抗癌药物对人体的不良影响
    • 机会
      • 政府增加对新兴国家医疗保健产业的资助
      • 新兴经济体卵巢癌药物的趋势
    • 任务
      • 治疗卵巢癌的费用很高
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依治疗层级的卵巢癌治疗药物市场

  • 血管新生抑制剂
  • PARP抑制剂
  • PD-L1抑制剂

第七章卵巢癌治疗药物市场：按方式

  • 化疗
  • 荷尔蒙疗法
  • 标靶治疗

第八章卵巢癌治疗药物市场（按药物）

  • Avastin
  • Carboplatin
  • Doxil
  • 林帕尔札
  • Yondelis

第九章北美和南美卵巢癌药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区卵巢癌药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲卵巢癌药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Alkem Laboratories Ltd.
  • Allergan PLC
  • AstraZeneca PLC
  • Boehringer Ingelheim
  • Cipla Ltd.
  • Clovis Oncology
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi India Pvt. Ltd.
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Mylan Pharmaceuticals Pvt. Ltd.
  • Pfizer, Inc.
  • Sanofi SA
  • Syndax Pharmaceuticals, Inc.
Product Code: MRR-434CCDA052A2

The Ovarian Cancer Drugs Market was valued at USD 3.95 billion in 2023, expected to reach USD 4.49 billion in 2024, and is projected to grow at a CAGR of 13.75%, to USD 9.73 billion by 2030.

The scope of the ovarian cancer drugs market encompasses the development, production, and distribution of pharmacological treatments specifically designed to target ovarian cancer. This includes chemotherapeutic agents, targeted therapies, and immunotherapies. The necessity of ovarian cancer drugs is underscored by the high mortality rates associated with ovarian cancer, largely due to the often late-stage diagnosis, making effective drug therapies vital for improving survival rates and patient outcomes. Applications primarily include usage by oncologists and healthcare facilities for treatment regimes, with end-use spanning hospitals, specialty cancer treatment centers, and clinics.

KEY MARKET STATISTICS
Base Year [2023] USD 3.95 billion
Estimated Year [2024] USD 4.49 billion
Forecast Year [2030] USD 9.73 billion
CAGR (%) 13.75%

Market growth is significantly influenced by factors such as advancements in personalized medicine, increased R&D investments, and expanding global awareness of the disease. The rise of innovative therapies, including targeted and combination therapies, offers substantial growth potential, as does the increasing regulatory approval of novel drugs. The growing demand for minimally invasive treatment options and improved therapeutic outcomes also creates new opportunities for market expansion. Recommendations to capitalize on these opportunities include investing in precision oncology and enhancing patient access through strategic partnerships.

However, the market faces limitations such as high drug development costs, stringent regulatory requirements, and potential side effects associated with existing therapies. Additionally, the genetic diversity of ovarian cancer makes it challenging to develop a one-size-fits-all treatment, often requiring complex treatment strategies.

Areas ripe for innovation include the development of biomarkers for early detection, novel drug delivery systems, and patient-specific treatment options leveraging artificial intelligence and genomic insights. Furthermore, the nature of the market is competitive yet collaborative, involving partnerships between pharmaceutical firms, biotechnology companies, and research institutions. Companies that focus on breakthrough therapies and adaptive clinical trial designs are well-positioned to lead in this evolving market landscape. Given these dynamics, stakeholders should prioritize patient-centric design and digitally integrated healthcare solutions to foster long-term innovation and growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Ovarian Cancer Drugs Market

The Ovarian Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of ovarian cancer around the globe
    • Increasing geriatric population of women around the world
    • Adoption of novel drugs and strong developmental pipeline
  • Market Restraints
    • Adverse impact of cancer drugs on the human body
  • Market Opportunities
    • Rising funding in the healthcare industry by the government in developing countries
    • Developments in ovarian cancer drugs in emerging economies
  • Market Challenges
    • Cost associated with the treatment of ovarian cancer is high

Porter's Five Forces: A Strategic Tool for Navigating the Ovarian Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Ovarian Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Ovarian Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Ovarian Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Ovarian Cancer Drugs Market

A detailed market share analysis in the Ovarian Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Ovarian Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Ovarian Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Ovarian Cancer Drugs Market

A strategic analysis of the Ovarian Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Ovarian Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alkem Laboratories Ltd., Allergan PLC, AstraZeneca PLC, Boehringer Ingelheim, Cipla Ltd., Clovis Oncology, F. Hoffmann-La Roche AG, Fresenius Kabi India Pvt. Ltd., GlaxoSmithKline PLC, Merck & Co., Inc., Mylan Pharmaceuticals Pvt. Ltd., Pfizer, Inc., Sanofi S.A., and Syndax Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Ovarian Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapeutics Class, market is studied across Angiogenesis Inhibitors, PARP Inhibitors, and PD-L1 Inhibitors.
  • Based on Modality, market is studied across Chemotherapy, Hormonal Therapy, and Targeted Therapy.
  • Based on Drugs, market is studied across Avastin, Carboplatin, Doxil, Lynparza, and Yondelis.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of ovarian cancer around the globe
      • 5.1.1.2. Increasing geriatric population of women around the world
      • 5.1.1.3. Adoption of novel drugs and strong developmental pipeline
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse impact of cancer drugs on the human body
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising funding in the healthcare industry by the government in developing countries
      • 5.1.3.2. Developments in ovarian cancer drugs in emerging economies
    • 5.1.4. Challenges
      • 5.1.4.1. Cost associated with the treatment of ovarian cancer is high
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Ovarian Cancer Drugs Market, by Therapeutics Class

  • 6.1. Introduction
  • 6.2. Angiogenesis Inhibitors
  • 6.3. PARP Inhibitors
  • 6.4. PD-L1 Inhibitors

7. Ovarian Cancer Drugs Market, by Modality

  • 7.1. Introduction
  • 7.2. Chemotherapy
  • 7.3. Hormonal Therapy
  • 7.4. Targeted Therapy

8. Ovarian Cancer Drugs Market, by Drugs

  • 8.1. Introduction
  • 8.2. Avastin
  • 8.3. Carboplatin
  • 8.4. Doxil
  • 8.5. Lynparza
  • 8.6. Yondelis

9. Americas Ovarian Cancer Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Ovarian Cancer Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Ovarian Cancer Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Alkem Laboratories Ltd.
  • 3. Allergan PLC
  • 4. AstraZeneca PLC
  • 5. Boehringer Ingelheim
  • 6. Cipla Ltd.
  • 7. Clovis Oncology
  • 8. F. Hoffmann-La Roche AG
  • 9. Fresenius Kabi India Pvt. Ltd.
  • 10. GlaxoSmithKline PLC
  • 11. Merck & Co., Inc.
  • 12. Mylan Pharmaceuticals Pvt. Ltd.
  • 13. Pfizer, Inc.
  • 14. Sanofi S.A.
  • 15. Syndax Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. OVARIAN CANCER DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. OVARIAN CANCER DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. OVARIAN CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. OVARIAN CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. OVARIAN CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. OVARIAN CANCER DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY AVASTIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CARBOPLATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY DOXIL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY LYNPARZA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY YONDELIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 148. OVARIAN CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. OVARIAN CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023